Cogent Biosciences (COGT) Projected to Post Earnings on Friday

Cogent Biosciences (NASDAQ:COGT) is anticipated to issue its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($0.5573) per share and revenue of $0.75 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings results on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, analysts expect Cogent Biosciences to post ($2.23) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

Cogent Biosciences Stock Performance

Shares of NASDAQ:COGT opened at $31.06 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 13.57 and a quick ratio of 13.57. Cogent Biosciences has a fifty-two week low of $13.78 and a fifty-two week high of $43.73. The firm’s 50 day simple moving average is $32.18 and its 200 day simple moving average is $35.64. The company has a market capitalization of $5.39 billion, a price-to-earnings ratio of -14.38 and a beta of 0.36.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a report on Wednesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, September 15th. Guggenheim upped their target price on Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen cut shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues.

Cogent’s lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease.

Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs.